Immunotherapy in Gastrointestinal Cancers

Area of Science:

• Oncology
• Gastroenterology
• Immunology

Background:

• Immunotherapy has transformed cancer care, offering durable responses in previously terminal cases.
• Its application in gastrointestinal (GI) cancers is an evolving field with significant potential.

Purpose of the Study:

• To review phase 3 clinical trial evidence for immunotherapy in various GI cancers.
• To discuss biomarkers, clinical challenges, and future strategies for immunotherapy in GI malignancies.

Main Methods:

• Analysis of current phase 3 clinical trial data for immunotherapy in GI cancers.
• Review of biomarkers such as mismatch-repair deficiency (MMRd)/microsatellite instability (MSI) and PD-L1 immunohistochemistry (IHC).

Main Results:

• Immunotherapy demonstrates efficacy in specific GI cancer patient populations.
• Biomarkers like MMRd/MSI and PD-L1 IHC are crucial for patient selection.
• Clinical questions persist regarding perioperative use, surgical timing, and GI-specific toxicities.

Conclusions:

• Immunotherapy is a key treatment modality for GI cancers, with ongoing research into optimizing its use.
• Future strategies involve combination therapies to enhance checkpoint blockade effectiveness.
• Further investigation is needed to address perioperative settings and specific toxicities in GI malignancies.